Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute

Medical Oncology

Volumn 32, Issue 4, 2015, Pages 1-11

  Segura González, Manuel ^a,b   Quintana Quintana, Miguel ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Capecitabine; Maintenance therapy; Recurring or metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DIARRHEA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEXICO; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FOLLOW UP; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CAPECITABINE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84958172245     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0533-y     Document Type: Article

References (49)

1. El Shagir N, Tfayli A, Hatoum H, Nachef Z, Dinh P, et al. Treatment of metastatic breast cáncer: state of the art subtypes and perspectives. Crit Rev Oncol Hematol. 2011;80:433–49.
2. Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, et al. Impact on survival of early detection of isolated breast recurrences after primary treatment for breast cáncer: a meta analysis. Breast Cancer Res Treat. 2009;114:403–12.
3. Sanphner T, Tormey DC, Gray R. Annual hazard rates of recurrences for breast cáncer after primary therapy. J Clin Oncol. 1996;14:2738–46.
4. Fernandez Y, Cueva J, Palomo AG, Ramos M, De Juan A, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33–42.
5. Lv YG, Yu F, Yao Q, Chen JH, Wang L, et al. The role of surviving in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2:100–10.
6. Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther. 2009;31:2273–9.
7. Cardoso F, Bedard PL, Winer EP, Pasani O, Senkus-konefka E, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single agent chemotherapy. J Natl Cancer Inst. 2009;101:1174–81.
8. Miles D, Von Minckwitz G, Seidman AD. Combination vs sequential single agent therapy in metastatic breast cancer. Oncologist. 2002;7:13–9.
9. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, et al. Single agent vs combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;2:CD003372.
10. Sanchez Muñoz A, Perez-Ruiz E, Ribelles N, Marquez A, Alba E. Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther. 2008;12:1907–12.
11. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.
12. Wagstaff A, Ibbotson T, Goa K. Capecitabine, a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63:217–36.
13. Tarbot DC, Moiseyenko V, Van Belle S, et al. Randomised phase II trial comparing oral capecitabine with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 2002;86:1367–72.
14. Blum JL, Jones SE, Budzar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–93.
15. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759–68.
16. Cervantes G, Torrecillas L, Erazo AA, et al. Capecitabine as treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Oncol. 2000;19:121.
17. Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Capecitabine in patients with advanced breast cancer previously treated with anthracyclines and taxanes: results of large phase II study. Proc Am Soc Clin Oncol. 2002;21:62.
18. Jakob A, Bokemeyer C, Knop S, et al. Capecitabine in patients with breast cancer relapsing after high dose chemotherapy plus autologous peripheral stem cell transplantation, a phase II study. Anticancer Drugs. 2002;13:405–10.
19. Reichardt P, Von Minckwitz G, Lück HJ, et al. Capecitabine the new standard in metastatic breast cancer failing anthracycline and taxane containing chemotherapy? Mature results of a large multicenter phase II trial. EJC. 2001;37:191.
20. Wong ZW, Wong KK, Chew L et al. Capecitabine as an oral chemotherapy agent in the treatment of refractory metastatic breast cancer. 36th annual meeting of the American Society of Clinical Oncology 2000;19:20.
21. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–23.
22. Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–7.
23. Sparano JA, Vrdoljak E, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with anthracycline and a taxane. J Clin Oncol. 2010;28:3256–63.
24. O’Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized open label, phase II trial of oral capecitabine versus a reference arm of intravenous CMF as first line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001;12:1247–54.
25. Meza LA, Amin B, Horsey M et al. A phase II study of capecitabine in combination with paclitaxel as first of second line therapy in patients with metastatic breast cancer. 37th annual meeting of the American Society of Clinical Oncology 2001;20:70.
26. Venturini M, Catzeddu T, Durando A, et al. A multicenter phase II study of TEX regimen (Taxotere, Epirubicin, and Xeloda) as first line treatment in advanced breast cancer. Ann Oncol. 2001;4:25.
27. Kattan J, Ghosn M, Farhat F, et al. Phase II study of vinorelbine and capecitabine combination as first line treatment of metastatic breast cancer. Ann Oncol. 2002;5:56.
28. Xu L, Song S, Zhu J, et al. Capecitabine + Trastuzumab as first line treatment in patients with Her 2 positive metastatic breast cancer: a phase II trial results. Breast Cancer Res Treat. 2006;100:s102.
29. Yamamoto D, Iwase S, Kitamura K, et al. A phase II study of trastuzumab and capecitabine for patients with Her 2- overexpressing metastatic breast cancer: Japan breast cancer research network (JBCRN) 00 trial. Cancer Chemother Pharmacol. 2008;61:509–14.
30. Wardley A, Antón-Torres A, Pivot X et al. Trastuzumab plus docetaxel with or without capecitabine as firts line therapy for Her 2-positive locally advanced or metastatic breast cancer: a randomised phase II study. Eur J Cancer Suppl. 2008;109:abstract 209.
31. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2 positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27:1999–2006.
32. Geyer CE, Foster J, Lindquist D, et al. Lapatinib plus capecitabine for Her 2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.
33. Gray R, Bhattacharya S, Bowden C, Miller K, Comis R, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966–72.
34. Miles D, Chan A, Dirix L, Cortés J, Pivot X, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first line treatment of human epidermal growth factor negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.
35. Robert N, Dieras V, Glaspy J, Brufsky A, Bondarenko I, et al. RIBBON-1: randomized, double blind, placebo-controlled, phase III trial chemotherapy with or without bevacizumab for first line treatment of human epidermal growth factor receptor 2 negative locally, recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.
36. Brofsky A, Hurvitz S, Perez E, Swamy R, Valero V, et al. RIBBON-2: a randomized, double blind, placebo controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second line treatment of human epidermal gorwth factor receptor 2 negative metastatic breast cancer. J Clin Oncol. 2011;29:4286–93.
37. Huang H, Jiang Z, Wang T, Zhang S, Bian L, et al. Single agent capecitabine maintenance therapy after response to capecitabine based combination chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2012;23:718–23.
38. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3.2012.
39. Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat LT, et al. Eribulin monotherapy versus treatment of physician choice in patientes with metastatic breast cancer: a phase 3 open label randomised study. Lancet. 2011;377:914–23.
40. Gennari A, Stockler M, Pontoni M, Sormani M, Nanni O, et al. Duration of chemotherapy for metastatic breast cancer: A systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29:2144–9.
41. Muss H, Case LD, Richards F, White D, Cooper R, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med. 1991;325:1342–8.
42. Coates A, Stockler M, Wilcken N, et al. Controversies in metastatic breast cancer: optimal duration of CT. Am Soc Clin Oncol Educ Book. 2003;119–21.
43. Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. 2010;122:169–76.
44. Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, et al. Lack of benefit of maintenance paclitaxel in first line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006;24:3912–8.
45. Dufresne A, Pivot X, Tournigand C, Facchini T, Alweeg T, et al. Maintenance hormonal treatment improves progression free survival after first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci. 2008;5:100–5.
46. Fabi A, Russillo M, Ferratti G, Metro G, Nistico C, et al. Maintenance bevacizumab beyond first line paclitaxel plus bevacizumab in patients with Her 2 negative, hormone receptor positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer. 2012;12:1–7.
47. Bisagni G, Musolino M, Panebianco M, De Matties F, Nuzzo F, et al. The breast Avastin trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first line treatment of patients with locally recurrent or metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71:1051–7.
48. Goldhirsch A, Winer EP, Wood W, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Experto Consensus of primary therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2203–23.
49. Von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann W, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.